Lexeo Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 24, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 24, 2025

LXEO$3.14+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

(In thousands)

	Year Ended December 31,
2024 · 2023
Cash flows from operating activities:
Net loss		$(98,333)		$(66,394)
Adjustments to reconcile net loss to net cash used in operating activities:
Reduction in the carrying amount of ROU assets, operating		1,373		1,266
Reduction in the carrying amount of ROU assets, finance		325		306
Stock based compensation expense		12,474		3,043
Depreciation and amortization expense		304		271
Change in fair value of convertible SAFE Note liability		-		530
Accretion of discount on investments		(23)		-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(1,690)		990
Accounts payable		2,378		(180)
Accrued expenses and other current liabilities		3,367		2,091
Lease liabilities, operating		(1,336)		(1,414)
Lease liabilities, finance		10		(5)
Net cash used in operating activities		(81,151)		(59,496)
Cash flows from investing activities:
Purchase of internal use software		-		(50)
Purchase of property and equipment		(481)		(115)
Purchases of investments		(93,596)		-
Net cash used in investing activities		(94,077)		(165)
Cash flows from financing activities:
Proceeds from exercise of stock options		491		51
Payments on finance leases		(410)		(425)
Treasury stock repurchases		(17)		-
Payments of issuance costs on convertible SAFE Note		-		(86)
Proceeds from issuance of convertible SAFE Note		-		4,000
Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs		88,712		-
Proceeds from issuance of common stock upon initial public offering, net of underwriters' discounts, commissions and other offering costs		-		100,251
Net cash provided by financing activities		88,776		103,791
Net change in cash, cash equivalents and restricted cash		(86,452)		44,130
Cash, cash equivalents and restricted cash at beginning of period		124,718		80,588
Cash, cash equivalents and restricted cash at end of period		$38,266		$124,718
Supplemental disclosures of cash flow information
Interest paid		$127		$176
Supplemental disclosure of non-cash activities
Deferred offering costs included in accounts payable and accrued expenses	$	-		$1,105
Unrealized loss on investments		$(103)	$	-
Reclassification of internal use software into prepaid expenses		$98	$	-
Issuance costs related to convertible debt included in accounts payable and accrued expenses	$	-		$50
(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable		$(120)		$141
Finance lease right-of use assets and finance lease liabilities recognized		$22	$	-
Conversion of convertible preferred stock into common stock in connection with initial public offering, net of issuance costs	$	-		$185,032
Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs	$	-		$4,417
Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities		$59		$87

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.